Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Dexcel-Pharma Ltd., 7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire NN11 8PB, UK
ViePax XL 75 mg prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablets. White convex capsule shaped coated tablets. |
Each tablet contains 75 mg venlafaxine (as venlafaxine hydrochloride).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Venlafaxine |
Venlafaxine has an antidepressant effect. The mechanism of its action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system. |
| List of Excipients |
|---|
|
Core: Microcrystalline cellulose Coating: Ethylcellulose |
The tablets are presented in aluminium/ACLAR-coated-PVC blisters, or aluminium/PVC/PE/PVDC blisters, strips of which are contained within a printed cardboard carton. ViePax XL 75 mg comes in calendar packs of 28 tablets.
Dexcel-Pharma Ltd., 7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire NN11 8PB, UK
PL 14017/0118
19/11/2008
| Drug | Countries | |
|---|---|---|
| VIEPAX | Israel, Singapore, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
